Evidence map›Paper›PMID 37711004›Full record

ReviewMini reviews in medicinal chemistry2024

Ebselen: A Review on its Synthesis, Derivatives, Anticancer Efficacy and Utility in Combating SARS-COV-2.

Farak Ali, Shahnaz Alom, Sheikh Rezzak Ali, Biswanarayan Kondoli, Prativa Sadhu, Chinmoyee Borah, Bibhuti Bushan Kakoti, Surajit Kumar Ghosh, Anshul Shakya, Abdul Baquee Ahmed and 2 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in Mini reviews in medicinal chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Farak AliDepartment of Pharmaceutical Sciences, Dibrugarh University, Dibrugarh, Assam, 786004, India.
Shahnaz AlomDepartment of Pharmaceutical Sciences, Dibrugarh University, Dibrugarh, Assam, 786004, India.
Sheikh Rezzak AliDepartment of Pharmaceutical Sciences, Dibrugarh University, Dibrugarh, Assam, 786004, India.
Biswanarayan KondoliDepartment of Pharmacy, Tripura University, Suryamani Nagar, Agartala, Tripura 799022, India.
Prativa SadhuDepartment of Pharmaceutical Sciences, Dibrugarh University, Dibrugarh, Assam, 786004, India.
Chinmoyee BorahGirijananda Chowdhury Institute of Pharmaceutical Science, Guwahati, Kamrup, Assam, 781017, India.
Bibhuti Bushan KakotiDepartment of Pharmaceutical Sciences, Dibrugarh University, Dibrugarh, Assam, 786004, India.
Surajit Kumar GhoshDepartment of Pharmaceutical Sciences, Dibrugarh University, Dibrugarh, Assam, 786004, India.
Anshul ShakyaDepartment of Pharmaceutical Sciences, Dibrugarh University, Dibrugarh, Assam, 786004, India.
Abdul Baquee AhmedGirijananda Chowdhury Institute of Pharmaceutical Science,Tezpur Medical College and Hospital, Tezpur, Sonitpur-784501, Assam, India.
Udaya Pratap SinghDrug Design & Discovery Laboratory, Department of Pharmaceutical Sciences, Sam Higginbottom University of Agriculture, Technology & Sciences, Allahabad, Uttar Pradesh, 211007, India.
Hans Raj BhatDepartment of Pharmaceutical Sciences, Dibrugarh University, Dibrugarh, Assam, 786004, India.

Funding

All India Council for Technical Education (AICTE), New Delhi, India 8-21/FDC/RPS (NER)/POLICY-1/2020-21
6 · The paper itself

Abstract

Ebselen is a selenoorganic chiral compound with antioxidant properties comparable to glutathione peroxidase. It is also known as 2-phenyl-1,2-benzisoselenazol-3(2H)-one. In studies examining its numerous pharmacological activities, including antioxidant, anticancer, antiviral, and anti- Alzheimer's, ebselen has demonstrated promising results. This review's primary objective was to emphasize the numerous synthesis pathways of ebselen and their efficacy in fighting cancer. The data were collected from multiple sources, including Scopus, PubMed, Google Scholar, Web of Science, and Publons. The starting reagents for the synthesis of ebselen are 2-aminobenzoic acid and N-phenyl benzamide. It was discovered that ebselen has the ability to initiate apoptosis in malignant cells and prevent the formation of new cancer cells by scavenging free radicals. In addition, ebselen increases tumor cell susceptibility to apoptosis by inhibiting TNF-α mediated NF-kB activation. Ebselen can inhibit both doxorubicin and daunorubicin-induced cardiotoxicity. Allopurinol and ebselen administered orally can be used to suppress renal ototoxicity and nephrotoxicity. Due to excessive administration, diclofenac can induce malignancy of the gastrointestinal tract, which ebselen can effectively suppress. Recent research has demonstrated ebselen to inhibit viral function by binding to cysteinecontaining catalytic domains of various viral proteases. It was discovered that ebselen could inhibit the catalytic dyad function of M

Indexed as

Antineoplastic AgentsAntiviral AgentsAzolesCOVID-19 Drug TreatmentIsoindolesOrganoselenium CompoundsSARS-CoV-2AnimalsAntioxidantsApoptosisCOVID-19HumansNeoplasmsAntineoplastic AgentsAntioxidantsAntiviral AgentsAzolesebselenIsoindolesOrganoselenium CompoundsanticancercytoprotectiveEbselenglutathione peroxidaseSARS-CoV-2.seleno-organic

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.